0.0600CAD+9.09%Mkt Cap: 11.87M CADP/E: —Last update: 2026-06-01
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II cli…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap11.87M CAD
Enterprise Value13.45M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.71M CAD
Revenue/Share—
Last Price0.0600 CAD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.39
PEG—
EV/EBITDA-3.43
EV/Revenue—
P/S—
P/B-2.89
EPS (TTM)-0.03
EPS (Forward)-0.14
52W Range
0.040017% of range0.1600
52W High0.1600 CAD
52W Low0.0400 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE94.80%
ROA-556.61%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.53M CAD
CapEx (TTM)—
FCF Margin—
FCF Yield-35.14%
Net Debt2.14M CAD
Net Debt/EBITDA-0.55
Balance Sheet
Debt/Equity-0.72
Current Ratio1.54
Quick Ratio1.52
Book Value/Sh-0.0190 CAD
Cash/Share0.0070 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 30, 2020
Splits
Last Split1:20
Split DateDec 30, 2020
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.197.82M
Float149.39M
Insiders17.76%
Institutions0.00%
Short Interest
Short Ratio0.2d
Short % Out.0.00%
Shares Short16.34K
Short (prev mo.)5.16K
Technical
SMA 500.0637 (-5.8%)
SMA 2000.0847 (-29.2%)
Beta0.58
S&P 52W Chg27.70%
Avg Vol (30d)43.59K
Avg Vol (10d)51.76K
Technical Indicators
RSI (14)41.6
MACD-0.0033
MACD Signal-0.0031
MACD Hist.-0.0002
BB Upper0.0679 CAD
BB Middle0.0590 CAD
BB Lower0.0501 CAD
BB Width30.32%
ATR (14)0.0051 CAD
Vol Ratio (20d)0.04x